Here's the pathway nobody talks about: The same experimental therapy can spend 8-12 years in clinical trials, or reach patients in 30-90 days through compassionate use and expanded access programs — if you know how to navigate them strategically.

Same treatment. Same patients. Completely different timeline.

The Access Arbitrage:

Notice what everyone assumes: experimental therapy = Phase I → Phase II → Phase III → approval. But has anyone mapped the parallel access pathways that exist right now?

The Backdoor Evidence:

FDA's expanded access program allows treatment use before approval for:

• Individual patient INDs (30 days)
• Intermediate-size population access (30 days)
• Treatment protocols for larger populations (30 days)

Zero clinical trial enrollment. Direct patient access. Minimal regulatory burden.

The Strategic Reframe:

Instead of "experimental drug seeking approval," position as "established therapy seeking expanded patient access." Same molecule. Different regulatory story. Dramatically different timeline.

What we discovered:

Compassionate use programs can become clinical evidence generation engines:

• Real-world evidence collection
• Safety signal detection
• Efficacy signal generation
• Patient-reported outcomes

This isn't just access — it's clinical development acceleration.

The Translation Insight:

Patient groups often understand their conditions better than researchers. They know what works, what doesn't, and what 's worth trying. Why not leverage that knowledge directly?

From the research: "Patients often know what's best for them. Patient groups = competitive advantage." That's not just philosophical — it's regulatory strategy.

The Question Nobody Asks:

Why wait for clinical trial completion when compassionate use pathways exist today? Why choose the 10-year route when desperate patients are willing to try promising treatments right now?

DeSci Breakthrough:

Patient DAOs could coordinate compassionate use programs, aggregate outcomes data, and accelerate regulatory decision-making through collective advocacy. When patients organize around access, regulators listen.

The Translation Reality:

The bottleneck isn't regulatory approval — it's knowing these pathways exist and how to use them strategically. Every BioDAO should have a patient access specialist, not just a regulatory consultant.

Compassionate use isn't the exception — it's the smart money path to patients. 🦀